Dr Catherine Lloyd O'brien, MD | |
53 Marion Rd, Suite 7, Wareham, MA 02571-1406 | |
(508) 295-5572 | |
(508) 291-2777 |
Full Name | Dr Catherine Lloyd O'brien |
---|---|
Gender | Female |
Speciality | Allergy & Immunology |
Location | 53 Marion Rd, Wareham, Massachusetts |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1205800810 | NPI | - | NPPES |
2046229 | Medicaid | MA | |
M08500 | Other | MA | BLUECROSS BLUESHIELD |
708925 | Other | MA | TUFTS HEALTH INSURANCE |
2237497 | Other | MA | UNITED HEALTHCARE |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207K00000X | Allergy & Immunology | 34833 (Massachusetts) | Primary |
Mailing Address | Practice Location Address |
---|---|
Dr Catherine Lloyd O'brien, MD 506 Fallbrook Dr, Venice, FL 34292-3149 Ph: (941) 496-4010 | Dr Catherine Lloyd O'brien, MD 53 Marion Rd, Suite 7, Wareham, MA 02571-1406 Ph: (508) 295-5572 |
News Archive
Allergan, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved BOTOX (onabotulinumtoxinA) for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency and frequency in adults who have had an inadequate response to or are intolerant of an anticholinergic medication.
First, Computerworld reports, "Verizon announced on Wednesday a new cloud-based service offering for healthcare providers that will handle the sharing of patient information electronically between disparate platforms. The new service, called the Verizon Health Information Exchange, consolidates clinical patient data from various providers and translates it into a standardized format that can then be accessed via a secure Web portal" (Mearian, 7/14).
Advances in genetic testing offer new insights to parents who have a child with a rare but serious form of epilepsy, epileptic encephalopathy (EE), found in one of about every 2,000 births and characterized by developmental disabilities as well as horrible seizures.
Inovio Pharmaceuticals, Inc. announced today that testing of multiple synthetic vaccine constructs for cytomegalovirus (CMV) induced robust T cells in mice, demonstrating the potential for a SynCon DNA vaccine to treat this virus that causes infant death and congenital abnormalities, is associated with cerebral palsy and brain tumors, and is the most common viral infection in organ transplant recipients. CMV is also associated with numerous inflammatory diseases and cancers, and is implicated in hypertension, a major risk factor for cardiovascular diseases.
› Verified 8 days ago